Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Binge drinking at time of bariatric surgery is associated with liver disease, suicides, and increases long-term mortality

  • Alvarado-Tapias, Edilmar|||0000-0003-2036-6133
  • Martí-Aguado, D.|||0000-0002-4266-6076
  • Gómez-Medina, C.|||0000-0002-4788-5630
  • Ferrero-Gregori, Andreu|||0000-0001-6492-2416
  • Szafranska, Justyna|||0000-0003-0467-8479
  • Brujats Rubirola, Anna|||0000-0003-3317-0295
  • Osuna Gómez, Rubén|||0000-0003-2875-4405
  • Alfaro-Cervelló, C.|||0000-0002-3737-4028
  • Pose, Elisa|||0000-0002-0224-7686
  • Ventura-Cots, Meritxell|||0000-0001-9513-2855
  • Fernández-Carrillo, C.|||0000-0002-1326-5142
  • Cabezas González, Joaquín|||0000-0003-0012-484X
  • López-Pelayo, Hugo|||0000-0002-3850-8374
  • Arab, Juan Pablo|||0000-0002-8561-396X
  • Argemi, J.|||0000-0003-1696-7753
  • Bataller, Ramon|||0000-0002-1119-7799
  • Guinart Cuadra, Albert|||0000-0003-0233-5595
  • Clemente-Sanchez, Ana
  • Contreras, Cynthia
Background and Aims: Alcohol use disorder has been reported in patients undergoing bariatric procedures, but the pattern of alcohol consumption has not been evaluated. We investigated the prevalence, risk factors, and impact of binge drinking (BD) at the time of surgery and during follow-up. Methods: A prospective, longitudinal study of subjects undergoing bariatric surgery was included in the LABS-2 registry between 2006 and 2009. Participants with AUDIT questionnaire at the time of surgery and a minimum of 12 months follow-up were included. BD was defined as consuming ≥5 drinks on at least 1 occasion in the previous month. Liver biopsies were obtained during bariatric procedures in not all cases. Survival analysis was performed with the adjusted Cox regression model and competing risk. Results: A total of 2257 subjects were included, with a median follow-up of 79 months. The prevalence of BD at time of surgery was 12%, and it raised up to 23% during follow-up. Patients with BD predominantly had a binge eating disorder (OR=1.35 [95% CI: 1.04-1.76]), regularly consumed fast food [OR=1.4 (95% CI: 1.07-1.85)] and used other drugs (OR=2.65 [95% CI: 1.74-4.04]). Within liver biopsies evaluation, BD showed higher hepatic iron deposits (OR=3.00 [95% CI: 1.25-7.21]). BD at the time of surgery was associated with a higher risk of BD during follow-up (OR=10.49 [95% CI: 7.86-14.00]) and long-term mortality (HR: 3.21 [95% CI: 1.67-6.18]). Specific causes of death in these patients with BD were liver disease (p=0.020), suicide (p=0.015), neoplasms (p=0.034), and respiratory (p=0.025). Conclusions: The prevalence of BD in patients undergoing bariatric surgery is high and increases the risk of postoperative liver disease, suicides, and long-term mortality.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The ANTICIPATE-NASH Models Stratify Better the Risk of Clinical Events Than Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Advanced Chronic Liver Disease

  • Aceituno, Laia|||0000-0001-5414-2408
  • Bañares, Juan|||0000-0002-1966-1947
  • Pons Delgado, Mònica|||0000-0002-0985-3320
  • Rivera Esteban, Jesús|||0000-0003-4357-8817
  • Sabiote, Clara
  • Cammà, Calogero
  • Ciancimino, Giacinta
  • Pennisi, Grazia
  • Tulone, Adele
  • Ma, Mang M.
  • Liu, X.
  • Watkins, Timothy R.
  • Billin, Andrew N.
  • Petta, Salvatore
  • Pericàs, Juan M.|||0000-0002-3645-3293
  • Abraldes, Juan G.|||0000-0003-3421-937X
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
Background & Aims: The reference for risk stratification and clinical trial selection of metabolic dysfunction-associated steatotic liver disease (MASLD) patients is fibrosis degree by histology. The noninvasive ANTICIPATE-NASH models have been validated for risk prediction of clinically significant portal hypertension (CSPH) and liver-related events (LRE). We assessed whether these models provide better risk stratification of events than histology. Methods: A multicenter cohort 1, including 699 biopsy specimen-proven F3-F4 patients with MASLD was evaluated. The end point was LRE (hepatic decompensation, hepatocellular carcinoma, transplantation, or liver-related death). We assessed (Cox regression) whether histology provided added value to ANTICIPATE-NASH and whether model predictions differed in F3/F4 patients. Results were validated in cohort 2 (1396 F3-F4 patients) from 4 clinical trials using the clinical regulatory end point. Results: In cohort 1, F3 and F4 were equally distributed. There were 56 LREs (8.0%) during follow-up, concentrated in F4 (51 LREs). The ANTICIPATE-NASH model showed excellent discrimination (C statistic, 0.93) for LRE, higher than histology (C statistic, 0.67). Model calibration was excellent. Adding histology did not improve model prediction. Thresholds of ANTICIPATE-NASH above which F3 patients developed LREs and below which F4 patients did not were identified. Results were reproduced in cohort 2 with the regulatory end point, with higher model discrimination (C statistic, 0.84) compared with histology (C statistic, 0.64). Conclusions: In MASLD patients with F3/F4, the noninvasive ANTICIPATE-NASH models provide better risk stratification of clinical events than histologic classification. These models could be very useful for clinical trials by selecting patients at risk of clinical events and patients with higher chances of observed cirrhosis regression.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes

  • Lazarus, Jeffrey V.|||0000-0001-9618-2299
  • Agirre-Garrido, Leire
  • Díaz, Luis Antonio
  • Danpanichkul, Pojsakorn
  • Kivuyo, Sokoine L.
  • Kondili, Loreta A.
  • Hagström, Hannes
  • Takahashi, Hirokazu
  • Pericàs, Juan M.|||0000-0002-3645-3293
  • Spearman, C. Wendy
  • Oliveira, Claudia P.
  • Villela-Nogueira, Cristiane A.
  • Schattenberg, Jörn M.
  • Toresson Grip, Emilie
  • Alkhouri, Naim
  • Marcellusi, Andrea
  • Mark, Henry E.
  • Allen, Alina M.
  • Carvalho Leite, Nathalie
  • Al-Omar, Hussain A.
  • Alqahtani, Saleh|||0000-0003-2017-3526
  • Brachowicz, Nicolai
What are the most cost-effective management approaches for detecting, preventing, and treating metabolic dysfunction-associated steatohepatitis and liver fibrosis among people living with type 2 diabetes (T2D) in 12 countries? This economic evaluation found that the standard of care had the lowest average cost-effectiveness ratios in 8 countries; intensive lifestyle interventions (ILIs) after screening were cost-effective in all countries; and ILIs and semaglutide or resmetirom therapy were cost-effective in 11 and 7 countries, respectively. In this study, most proposed management approaches among people living with T2D were cost-effective in most countries. This economic evaluation examines which approaches to the detection, prevention, and treatment of metabolic dysfunction-associated steatohepatitis (MASH) among individuals with type 2 diabetes are the most cost-effective across 12 countries, representing all 6 World Health Organization regions. Metabolic dysfunction-associated steatohepatitis (MASH) represents a high, underprioritized burden among noncommunicable diseases (NCDs) and people living with type 2 diabetes (T2D). To identify cost-effective management approaches to prevent, detect, and treat MASH and liver fibrosis in people living with T2D. This economic evaluation consisted of a generalized cost-effectiveness analysis (GCEA) that was conducted for 12 countries (Brazil, Chile, Germany, Italy, Japan, Saudi Arabia, South Africa, Spain, Sweden, Tanzania, Thailand, and the United States), across all 6 World Health Organization (WHO) regions. A cohort state-transition model simulated liver disease development and its impact on a synthetic cohort, aged 19 years and older and living with T2D, over their lifespan across 10 liver health states. Using an 80% coverage level, 14 management approaches were compared, including screening via the Fibrosis-4 (FIB-4) test and Enhanced Liver Fibrosis (ELF) test or vibration-controlled transient elastography (VCTE) as well as treatment with pharmacological and nonpharmacological interventions. The main outcomes were the average cost-effectiveness ratios (ACERs) and the incremental cost-effectiveness ratios (ICERs), which were used to construct care expansion paths by ranking the management approaches in order of cost-effectiveness. The main measures were the total incremental costs and the total incremental quality-adjusted life-years (QALYs) of each intervention. In this GCEA, the outcomes were evaluated with respect to country-specific willingness-to-pay thresholds. The standard of care had the lowest ACERs in 8 countries (not in Chile, Germany, Saudi Arabia, or the United States). Treatment with intensive lifestyle interventions (ILIs), after screening via ELF or VCTE, was cost-effective in all countries. ILIs and treatment with semaglutide was cost-effective in 11 countries (not in Tanzania); ILIs and treatment with resmetirom was cost-effective in 8 countries (not in Brazil, South Africa, Tanzania, or Thailand). In this economic evaluation, screening followed by ILIs was found to be a cost-effective management approach for MASH and liver fibrosis among people living with T2D in all countries. Screening followed by pharmacological treatment was cost-effective in most countries. These results can inform health policy decision-making and further the development of WHO recommended interventions to address NCDs.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Binge drinking at time of bariatric surgery is associated with liver disease, suicides, and increases long-term mortality

  • Alvarado-Tapias, Edilmar
  • Ferrero-Gregori, Andreu
  • Szafranska, Justyna
  • Brujats Rubirola, Anna
  • Ventura-Cots, Meritxell
  • Marti-Aguado, David
  • Gómez-Medina, Concepción
Binge drinking; Bariatric surgery; Liver disease, Consum excessiu d'alcohol; Cirurgia bariàtrica; Malalties hepàtiques, Consumo excesivo de alcohol; Cirugía bariátrica; Enfermedades hepáticas, Background and Aims: Alcohol use disorder has been reported in patients undergoing bariatric procedures, but the pattern of alcohol consumption has not been evaluated. We investigated the prevalence, risk factors, and impact of binge drinking (BD) at the time of surgery and during follow-up. Methods: A prospective, longitudinal study of subjects undergoing bariatric surgery was included in the LABS-2 registry between 2006 and 2009. Participants with AUDIT questionnaire at the time of surgery and a minimum of 12 months follow-up were included. BD was defined as consuming ≥5 drinks on at least 1 occasion in the previous month. Liver biopsies were obtained during bariatric procedures in not all cases. Survival analysis was performed with the adjusted Cox regression model and competing risk. Results: A total of 2257 subjects were included, with a median follow-up of 79 months. The prevalence of BD at time of surgery was 12%, and it raised up to 23% during follow-up. Patients with BD predominantly had a binge eating disorder (OR=1.35 [95% CI: 1.04–1.76]), regularly consumed fast food [OR=1.4 (95% CI: 1.07–1.85)] and used other drugs (OR=2.65 [95% CI: 1.74–4.04]). Within liver biopsies evaluation, BD showed higher hepatic iron deposits (OR=3.00 [95% CI: 1.25–7.21]). BD at the time of surgery was associated with a higher risk of BD during follow-up (OR=10.49 [95% CI: 7.86–14.00]) and long-term mortality (HR: 3.21 [95% CI: 1.67–6.18]). Specific causes of death in these patients with BD were liver disease (p=0.020), suicide (p=0.015), neoplasms (p=0.034), and respiratory (p=0.025). Conclusions: The prevalence of BD in patients undergoing bariatric surgery is high and increases the risk of postoperative liver disease, suicides, and long-term mortality., LABS-2 was funded by a cooperative agreement by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Grant numbers: Data Coordinating Center -U01 DK066557; Columbia-Presbyterian—U01-DK66667 (in collaboration with Cornell University Medical Center CTSC, Grant UL1-RR024996); University of Washington—U01-DK66568 (in collaboration with CTRC, Grant M01RR-00037); Neuropsychiatric Research Institute—U01-DK66471; East Carolina University—U01-DK66526; University of Pittsburgh Medical Center—U01 DK66585 (in collaboration with CTRC, Grant UL1-RR024153); Oregon Health & Science University—U01-DK66555. Ramon Bataller received lectures fee from Abbvie and Gilead. Hugo López-Pelayo received funds for training from Lundbeck and for elaborating training materials from Advanz Pharma. Joaquin Cabezas consults, advises, is on the speakers’ bureau, and received grants from Gilead. He is on the speakers’ bureau and received grants from Abbvie. Ramon Bataller is a recipient of NIAAA grants U01AA021908, U01AA020, and NIDDK P30DK120531821. Meritxell Ventura-Cots, Carlos Fernández-Carrillo, Edilmar Alvarado-Tapias, and Ana Clemente are recipients of a scholarship grant for study extension abroad, sponsored by the Spanish Association for the Study of the Liver (AEEH). Meritxell Ventura-Cots is recipient of a Joan Rodes award from the ISCII (JR19/00015) and the PI22/01770 grant from the ISCIII—Fondos Feder. Edilmar Alvarado-Tapias is a recipient of a Joan Rodes award from the ISCII (JR20/00047) and the PI21/01995 grant from the ISCIII- Fondos Feder. David Martí-Aguado is a recipient of the Joan Rodes award ISCIII (JR22/00002) and a scholarship grant for study extension abroad, sponsored by the University of Valencia (UV-RI_MID-1528578). Elisa Pose is a recipient of the PI22/00910 grant from the ISCIII—Fondos Feder. Josepmaria Argemi is a recipient of the PI20/01663 grant from the ISCIII- Fondos Feder and an award from the “Fundación Echebano” (Pamplona, Spain). Hugo López-Pelayo is a recipient of the PI20/00760 grant from the ISCIII—Fondos Feder, 2020I004 grant from Plan Nacional sobre Drogas, and 101045870 from DG Justice-European Commission. The remaining authors have no conflicts to report.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design

  • Al-Karaghouli, Mustafa
  • Bosques, Francisco
  • Brown, Robert
  • Ventura-Cots, Meritxell
  • Wong, Yu-Jun
  • Genesca, Joan
  • Vargas Blasco, Victor Manuel
Liver disease; Prognosis; Alcohol-associated hepatitis, Malaltia del fetge; Pronòstic; Hepatitis associada a l'alcohol, Enfermedad del hígado; Pronóstico; Hepatitis asociada al alcohol, Background: Alcohol-associated hepatitis (AH) is associated with significant mortality. Model for End-Stage Liver Disease (MELD) score is used to predict short-term mortality and aid in treatment decisions. MELD is frequently updated in the course of AH. However, once the most updated MELD is known, it is uncertain if previous ones still have prognostic value, which might be relevant for transplant allocation and trial design. We aimed to investigate the predictive performance of updated MELDs in a prospectively collected cohort of patients with AH by the InTeam consortium. Methods: Three hundred seven patients (with 859 MELD values within 60 d of admission) fulfilled the inclusion criteria. The main endpoint was time to death or transplant up to 90 days. We used a joint model approach to assess the predictive value of updated MELDs. Results: Updated MELD measurements had a strong prognostic value for death/transplant (HR: 1.20, 95% CI: 1.14–1.27) (p < 0.0001). Previous MELD values did not add predictive value to the most current MELD. We also showed that MELD at day 28 (MELD28) had a significant predictive value for subsequent mortality/transplant in a landmark analysis (HR: 1.18, 95% CI: 1.12–1.23). We show that the use of an ordinal scale including death, transplant, and MELD28 as a trial outcome could substantially reduce the sample size required to demonstrate short-term benefit of an intervention. Conclusion: We show that updated MELDs during the trajectory of AH predict subsequent mortality or the need for transplant. MELD28 inclusion in an ordinal outcome (together with death or transplant) could increase the efficiency of randomized controlled trials., This study was supported by the National Institutes on Alcohol Abuse and Alcoholism (NIAAA U01AA021908). Meritxell Ventura-Cots received financial support from JR19/00015 and PI22/01770. Bernd Schnabl is supported by NIH center P30 DK120515.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Liver steatosis induces portal hypertension regardless of fibrosis in patients with NAFLD, A proof of concept case report

Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Binge drinking at time of bariatric surgery is associated with liver disease, suicides, and increases long-term mortality

  • Alvarado-Tapias, Edilmar
  • Ferrero-Gregori, Andreu
  • Szafranska, Justyna
  • Brujats Rubirola, Anna
  • Ventura-Cots, Meritxell
  • Marti-Aguado, David
  • Gómez-Medina, Concepción
Binge drinking; Bariatric surgery; Liver disease, Consum excessiu d'alcohol; Cirurgia bariàtrica; Malalties hepàtiques, Consumo excesivo de alcohol; Cirugía bariátrica; Enfermedades hepáticas, Background and Aims: Alcohol use disorder has been reported in patients undergoing bariatric procedures, but the pattern of alcohol consumption has not been evaluated. We investigated the prevalence, risk factors, and impact of binge drinking (BD) at the time of surgery and during follow-up. Methods: A prospective, longitudinal study of subjects undergoing bariatric surgery was included in the LABS-2 registry between 2006 and 2009. Participants with AUDIT questionnaire at the time of surgery and a minimum of 12 months follow-up were included. BD was defined as consuming ≥5 drinks on at least 1 occasion in the previous month. Liver biopsies were obtained during bariatric procedures in not all cases. Survival analysis was performed with the adjusted Cox regression model and competing risk. Results: A total of 2257 subjects were included, with a median follow-up of 79 months. The prevalence of BD at time of surgery was 12%, and it raised up to 23% during follow-up. Patients with BD predominantly had a binge eating disorder (OR=1.35 [95% CI: 1.04–1.76]), regularly consumed fast food [OR=1.4 (95% CI: 1.07–1.85)] and used other drugs (OR=2.65 [95% CI: 1.74–4.04]). Within liver biopsies evaluation, BD showed higher hepatic iron deposits (OR=3.00 [95% CI: 1.25–7.21]). BD at the time of surgery was associated with a higher risk of BD during follow-up (OR=10.49 [95% CI: 7.86–14.00]) and long-term mortality (HR: 3.21 [95% CI: 1.67–6.18]). Specific causes of death in these patients with BD were liver disease (p=0.020), suicide (p=0.015), neoplasms (p=0.034), and respiratory (p=0.025). Conclusions: The prevalence of BD in patients undergoing bariatric surgery is high and increases the risk of postoperative liver disease, suicides, and long-term mortality., LABS-2 was funded by a cooperative agreement by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Grant numbers: Data Coordinating Center -U01 DK066557; Columbia-Presbyterian—U01-DK66667 (in collaboration with Cornell University Medical Center CTSC, Grant UL1-RR024996); University of Washington—U01-DK66568 (in collaboration with CTRC, Grant M01RR-00037); Neuropsychiatric Research Institute—U01-DK66471; East Carolina University—U01-DK66526; University of Pittsburgh Medical Center—U01 DK66585 (in collaboration with CTRC, Grant UL1-RR024153); Oregon Health & Science University—U01-DK66555. Ramon Bataller received lectures fee from Abbvie and Gilead. Hugo López-Pelayo received funds for training from Lundbeck and for elaborating training materials from Advanz Pharma. Joaquin Cabezas consults, advises, is on the speakers’ bureau, and received grants from Gilead. He is on the speakers’ bureau and received grants from Abbvie. Ramon Bataller is a recipient of NIAAA grants U01AA021908, U01AA020, and NIDDK P30DK120531821. Meritxell Ventura-Cots, Carlos Fernández-Carrillo, Edilmar Alvarado-Tapias, and Ana Clemente are recipients of a scholarship grant for study extension abroad, sponsored by the Spanish Association for the Study of the Liver (AEEH). Meritxell Ventura-Cots is recipient of a Joan Rodes award from the ISCII (JR19/00015) and the PI22/01770 grant from the ISCIII—Fondos Feder. Edilmar Alvarado-Tapias is a recipient of a Joan Rodes award from the ISCII (JR20/00047) and the PI21/01995 grant from the ISCIII- Fondos Feder. David Martí-Aguado is a recipient of the Joan Rodes award ISCIII (JR22/00002) and a scholarship grant for study extension abroad, sponsored by the University of Valencia (UV-RI_MID-1528578). Elisa Pose is a recipient of the PI22/00910 grant from the ISCIII—Fondos Feder. Josepmaria Argemi is a recipient of the PI20/01663 grant from the ISCIII- Fondos Feder and an award from the “Fundación Echebano” (Pamplona, Spain). Hugo López-Pelayo is a recipient of the PI20/00760 grant from the ISCIII—Fondos Feder, 2020I004 grant from Plan Nacional sobre Drogas, and 101045870 from DG Justice-European Commission. The remaining authors have no conflicts to report.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design

  • Al-Karaghouli, Mustafa
  • Bosques, Francisco
  • Brown, Robert
  • Ventura-Cots, Meritxell
  • Wong, Yu-Jun
  • Genesca, Joan
  • Vargas Blasco, Victor Manuel
Liver disease; Prognosis; Alcohol-associated hepatitis, Malaltia del fetge; Pronòstic; Hepatitis associada a l'alcohol, Enfermedad del hígado; Pronóstico; Hepatitis asociada al alcohol, Background: Alcohol-associated hepatitis (AH) is associated with significant mortality. Model for End-Stage Liver Disease (MELD) score is used to predict short-term mortality and aid in treatment decisions. MELD is frequently updated in the course of AH. However, once the most updated MELD is known, it is uncertain if previous ones still have prognostic value, which might be relevant for transplant allocation and trial design. We aimed to investigate the predictive performance of updated MELDs in a prospectively collected cohort of patients with AH by the InTeam consortium. Methods: Three hundred seven patients (with 859 MELD values within 60 d of admission) fulfilled the inclusion criteria. The main endpoint was time to death or transplant up to 90 days. We used a joint model approach to assess the predictive value of updated MELDs. Results: Updated MELD measurements had a strong prognostic value for death/transplant (HR: 1.20, 95% CI: 1.14–1.27) (p < 0.0001). Previous MELD values did not add predictive value to the most current MELD. We also showed that MELD at day 28 (MELD28) had a significant predictive value for subsequent mortality/transplant in a landmark analysis (HR: 1.18, 95% CI: 1.12–1.23). We show that the use of an ordinal scale including death, transplant, and MELD28 as a trial outcome could substantially reduce the sample size required to demonstrate short-term benefit of an intervention. Conclusion: We show that updated MELDs during the trajectory of AH predict subsequent mortality or the need for transplant. MELD28 inclusion in an ordinal outcome (together with death or transplant) could increase the efficiency of randomized controlled trials., This study was supported by the National Institutes on Alcohol Abuse and Alcoholism (NIAAA U01AA021908). Meritxell Ventura-Cots received financial support from JR19/00015 and PI22/01770. Bernd Schnabl is supported by NIH center P30 DK120515.